Navigation Links
GeneLink Reports Second Quarter Improvement
Date:8/18/2010

ORLANDO, Fla., Aug. 18 /PRNewswire-FirstCall/ -- GeneLink, Inc. (OTC Bulletin Board: GNLK), a leading applied genomics biotech company, reported financial results for the fiscal quarter ended June 30, 2010.

Financial Highlights:

  • Continued progress towards profitability: Quarterly operating loss reduced by 35% over Q2 2009
  • Comparable quarter gross profit improvement of 10% over Q2 2009
  • Six Month Revenues of $4,240,177 compared to $4,085,215 in the first six months of 2009

Gary Beeman, GeneLink's CEO stated, "In the first half of 2010, the Company continued to develop its position as the leader in genetically customized nutritional and personal care wellness solutions.  The second quarter of 2010 continues to reflect the positive impact of the steps initiated in late 2009 to increase our profit margins. Operating losses decreased by 35% and gross margin improved 10% as compared to the prior year.   GeneLink continues to focus its efforts on expansion of its current sales base while extending its sales and product offerings to new strategic and catalytic channels compatible with current initiatives."  

Dr. Bernard Kasten, GeneLink's Executive Chairman added, "In addition to the progress made within GeneLink during the second quarter, the past six months confirm what GeneLink has known for over a decade -- that genetic knowledge can be utilized to make almost any personal product more effective.  With key additions to executive management in first half of 2010, GeneLink is equipped to continue to develop our science, add new products, expand sales channels and execute our strategic plan."

About GeneLink Biosciences, Inc.:

GeneLink is a 16-year old leading biosciences company specializing in applied genomics. GeneLink's patented and patent pending technologies include proprietary genetic assessments and specific DNA tests used to guide the formulation and delivery of personalized health, beauty and wellness products. For more information visit www.genelinkbio.com

This release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GeneLink disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.


'/>"/>
SOURCE GeneLink, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... March 22, 2017 A new independent ... is the proven ultraviolet-C (UV-C) disinfection solution of ... (HAIs). Published in the March ... Control , the peer-reviewed study of UV-C disinfection ... Vancouver General Hospital and Rochester General Hospital. According ...
(Date:3/22/2017)... -- FinancialBuzz.com News Commentary  ... According to a report by the New Frontier ... in 2016, and is projected to grow at a compound annual ... by 2025. The medical cannabis market is projected to grow at ... to an estimated $13.3 billion in 2025. These projections do not ...
(Date:3/22/2017)... , March 22, 2017 TFS is ... and Mr. Ed Tumaian , two global executive positions in ... be joining the Operational Leadership Team and will report to Dr. ... ... comes to TFS with 10 years of medical and scientific expertise ...
Breaking Medicine Technology:
(Date:3/22/2017)... ... March 22, 2017 , ... The Rett Syndrome ... devastating neurological disorder that afflicts 350,000 individuals worldwide. Rett Syndrome is caused ... almost exclusively strikes females. Following a normal infancy, Rett Syndrome takes effect ...
(Date:3/22/2017)... , ... March 22, 2017 , ... Last year, 43 ... a US Department of Agriculture report. While excess dairy can be caused by ... role. Lactose sensitivity is the inability to properly digest lactose, a sugar found in ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Tyler Hitchcock Agency, a ... across eastern Texas, is announcing a charity drive in conjunction with the North ... adults. , Consistently a top-rated nonprofit organization for hunger relief, the North ...
(Date:3/22/2017)... ... 2017 , ... Martin J. Mitchell Insurance, a Columbus area ... central Ohio, is initiating a charity drive to raise support for nearby veterans ... the Veteran's Brain Injury Center conclude that more than one in five of ...
(Date:3/22/2017)... ... March 22, 2017 , ... NYC Chiropractor Dr. Steven Shoshany recently helped host ... its kind in the U.S. and focused on a new protocol for treating pain. ... to New York, and furthermore the first seminar in the country was hosted ...
Breaking Medicine News(10 mins):